Sara Westrøm1, Roman Generalov2, Tina B Bønsdorff3, Roy H Larsen4. 1. Oncoinvent AS, Oslo, Norway; Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2. Nordic Nanovector ASA, Oslo, Norway. 3. Oncoinvent AS, Oslo, Norway. 4. Oncoinvent AS, Oslo, Norway; Sciencons AS, Oslo, Norway. Electronic address: royhlars1@yahoo.no.
Abstract
INTRODUCTION: Alpha-emitting radionuclides have gained considerable attention as payloads for cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for this purpose is 212Pb, which by itself is a β-emitter, but acts as an in vivo generator for its short-lived α-emitting daughters. The standard method of preparing 212Pb-labeled antibodies requires handling and evaporation of strong acids containing high radioactivity levels by the end user. An operationally easier and more rapid process could be useful since the 10.6h half-life of 212Pb puts time constraints on the preparation protocol. In this study, an in situ procedure for antibody labeling with 212Pb, using a solution of the generator nuclide 224Ra, is proposed as an alternative protocol for preparing 212Pb-radioimmunoconjugates. METHODS: Radium-224, the generator radionuclide of 212Pb, was extracted from its parent nuclide, 228Th. Lead-212-labeling of the TCMC-chelator conjugated monoclonal antibody trastuzumab was carried out in a solution containing 224Ra in equilibrium with progeny. Subsequently, the efficiency of separating the 212Pb-radioimmunoconjugate from 224Ra and other unconjugated daughter nuclides in the solution using either centrifugal separation or a PD-10 desalting size exclusion column was evaluated and compared. RESULTS: Radiolabeling with 212Pb in 224Ra-solutions was more than 90% efficient after only 30min reaction time at TCMC-trastuzumab concentrations from 0.15mg/mL and higher. Separation of 212Pb-labeled trastuzumab from 224Ra using a PD-10 column was clearly superior to centrifugal separation. This method allowed recovery of approximately 75% of the 212Pb-antibody-conjugate in the eluate, and the remaining amount of 224Ra was only 0.9±0.8% (n=7). CONCLUSIONS: The current work demonstrates a novel method of producing 212Pb-based radioimmunoconjugates from a 224Ra-solution, which may be simpler and less time-consuming for the end user compared with the method established for use in clinical trials of 212Pb-TCMC-trastuzumab.
INTRODUCTION: Alpha-emitting radionuclides have gained considerable attention as payloads for cancer targeting molecules due to their high cytotoxicity. One attractive radionuclide for this purpose is 212Pb, which by itself is a β-emitter, but acts as an in vivo generator for its short-lived α-emitting daughters. The standard method of preparing 212Pb-labeled antibodies requires handling and evaporation of strong acids containing high radioactivity levels by the end user. An operationally easier and more rapid process could be useful since the 10.6h half-life of 212Pb puts time constraints on the preparation protocol. In this study, an in situ procedure for antibody labeling with 212Pb, using a solution of the generator nuclide 224Ra, is proposed as an alternative protocol for preparing 212Pb-radioimmunoconjugates. METHODS: Radium-224, the generator radionuclide of 212Pb, was extracted from its parent nuclide, 228Th. Lead-212-labeling of the TCMC-chelator conjugated monoclonal antibody trastuzumab was carried out in a solution containing 224Ra in equilibrium with progeny. Subsequently, the efficiency of separating the 212Pb-radioimmunoconjugate from 224Ra and other unconjugated daughter nuclides in the solution using either centrifugal separation or a PD-10 desalting size exclusion column was evaluated and compared. RESULTS: Radiolabeling with 212Pb in 224Ra-solutions was more than 90% efficient after only 30min reaction time at TCMC-trastuzumab concentrations from 0.15mg/mL and higher. Separation of 212Pb-labeled trastuzumab from 224Ra using a PD-10 column was clearly superior to centrifugal separation. This method allowed recovery of approximately 75% of the 212Pb-antibody-conjugate in the eluate, and the remaining amount of 224Ra was only 0.9±0.8% (n=7). CONCLUSIONS: The current work demonstrates a novel method of producing 212Pb-based radioimmunoconjugates from a 224Ra-solution, which may be simpler and less time-consuming for the end user compared with the method established for use in clinical trials of 212Pb-TCMC-trastuzumab.
Authors: Valery Radchenko; Alfred Morgenstern; Amir R Jalilian; Caterina F Ramogida; Cathy Cutler; Charlotte Duchemin; Cornelia Hoehr; Ferrid Haddad; Frank Bruchertseifer; Haavar Gausemel; Hua Yang; Joao Alberto Osso; Kohshin Washiyama; Kenneth Czerwinski; Kirsten Leufgen; Marek Pruszyński; Olga Valzdorf; Patrick Causey; Paul Schaffer; Randy Perron; Samsonov Maxim; D Scott Wilbur; Thierry Stora; Yawen Li Journal: J Nucl Med Date: 2021-07-22 Impact factor: 11.082
Authors: Brooke L McNeil; Andrew K H Robertson; Winnie Fu; Hua Yang; Cornelia Hoehr; Caterina F Ramogida; Paul Schaffer Journal: EJNMMI Radiopharm Chem Date: 2021-02-01
Authors: Ruth Gong Li; Kim Lindland; Tina Bjørnlund Bønsdorff; Sara Westrøm; Roy Hartvig Larsen Journal: Materials (Basel) Date: 2021-11-23 Impact factor: 3.623
Authors: Sara Westrøm; Marion Malenge; Ida Sofie Jorstad; Elisa Napoli; Øyvind S Bruland; Tina B Bønsdorff; Roy H Larsen Journal: J Labelled Comp Radiopharm Date: 2018-03-12 Impact factor: 1.921
Authors: José Carlos Dos Santos; Martin Schäfer; Ulrike Bauder-Wüst; Wencke Lehnert; Karin Leotta; Alfred Morgenstern; Klaus Kopka; Uwe Haberkorn; Walter Mier; Clemens Kratochwil Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-03 Impact factor: 9.236
Authors: Konstantin V Kokov; Bayirta V Egorova; Marina N German; Ilya D Klabukov; Michael E Krasheninnikov; Antonius A Larkin-Kondrov; Kseniya A Makoveeva; Michael V Ovchinnikov; Maria V Sidorova; Dmitry Y Chuvilin Journal: Pharmaceutics Date: 2022-01-13 Impact factor: 6.321